Atezolizumab

Red

Brand Name(s):Tecentriq

Indication:Advanced or Unresectable Hepatocellular Carcinoma in Adults

Urothelial carcinoma (locally advanced or metastatic )
Lung cancer- metastatic non-squamous non-small cell lung cancer (NSCLC). should be used in combination therapy (bevacizumab, paclitaxel and carboplatin)

Rationale:1,2,3

Considered:Oct-17

Review Date:May-26

Comments:
Safety alert
Manufacturers warn that SCARs, including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported. Patients should be monitored for severe skin reactions. In case a SCAR is suspected, treatment should be withheld and patients should be referred to a specialist.
April 2021

NICE TA666 recommends atezolizumab plus bevacizumab as an option for treating advanced or unresectable hepatocellular carcinoma in adults who have not had previous systemic treatment, only if they have Child Pugh grade A liver impairment and an ECOG performance status of 0 or 1.

NICE TA638 states Atezolizumab with carboplatin and etoposide is recommended as an option for untreated extensive-stage small-cell lung cancer in adults, only if they have an ECOG performance status of 0 or 1, and the company provides atezolizumab according to the commercial arrangement.